Using 18F-MFBG PET/CT to evaluate neural crest tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) PET imaging in patients with neuroendocrine tumors, specifically pheochromocytoma, paraganglioma, and neuroblastoma. The study will evaluate the safety profile and image quality of 18F-MFBG, which targets the norepinephrine transporter (NET) expressed in these tumors. Unlike traditional imaging methods, 18F-MFBG allows for earlier imaging after injection, potentially improving diagnosis and treatment planning. Patients with confirmed or suspected neural crest tumors will be prospectively recruited for this evaluation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- The subject has read, signed, and dated an informed consent form (ICF) prior to any study procedures being performed. Patients with histologically confirmed or clinically suspicious neural crest tumor.

For patients with neuroblastoma, subject should have a routine clinical 123I-MIBG scintigraphy (planar + SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.

The subject is male or is a nonpregnant, nonlactating female who is either surgically sterile or is post-menopausal. The subject is able and willing to comply with all study procedures as described in the protocol.

Exclusion Criteria:

\- Patients are potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding.

Patients undergo surgery between the selection and inclusion visit. Patients who are pregnant, may possibly be pregnant, or wish (including their partners) to become pregnant during the study period, or are lactating. Patients who are not suitable to participate in the trial according to researchers.

Where it's running

• Peking union medical college hospital
  Beijing, Dongcheng, China Recruiting

Study contacts

• Principal investigator: Fang Li — Peking Union Medical College Hospital
• Study coordinator: Peipei Wang
• Email: wpp199411@163.com
• Phone: 18511395988

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Understanding genetic causes of neuroendocrine tumors in Mexican patients

  This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.

  Recruiting at 3 sites Universidad Nacional Autonoma de Mexico · Mexico City, Mexico City and 2 other locations · NCT06523582

• Examining the immune system in hereditary pheochromocytoma and paraganglioma

  This study is testing how the immune system works in people with pheochromocytoma and paraganglioma, especially those with a family history of these tumors, to see if it can help us find better treatments.

  Recruiting Radboud University Medical Center · Nijmegen, Gelderland · NCT06444607

• Advancing genomic medicine using electronic health records

  This study is trying to see if using electronic health records and helpful reminders can get more patients tested for genetic conditions in a way that doctors can easily use.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT06377033

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.